Discover how the latest population-based analysis reveals comparable long-term effects of frontline therapies BR and RCVP in the battle against Waldenström macroglobulinemia, offering new hope for patients seeking effective treatment options.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Kim et al., Leuk Lymphoma 2023
DOI: 10.1080/10428194.2023.2290466
Study Findings: A comparison of two treatment regimens for Waldenström macroglobulinemia (WM), bendamustine-rituximab (BR) and rituximab-cyclophosphamide-vincristine-prednisone (RCVP), was conducted on 111 treatment-naïve patients. The median follow-up period was 60.7 months. The median progression-free survival (PFS) was similar for both treatments: 60.5 months for BR and 79.0 months for RCVP, with no significant difference (p=.96). Median overall survival (OS) was not reached for BR and was 153.4 months for RCVP, also not significantly different (p=.37). BR showed a higher, but not statistically significant, rate of very good partial response or better (51% vs. 37%, p=.30) and complete response (26% vs. 13%, p=.13).
Importance: This study suggests that RCVP is as effective as BR for treating TN WM, which is particularly relevant for patients with tolerance or frailty issues, or in settings with limited resources.
Contribution to Literature: The research provides evidence that RCVP can be considered a viable frontline treatment option for TN WM, offering comparable outcomes to the more commonly used BR regimen.